Mid-dilution hemodiafiltration (MID) is a dialytic technique that might improve systemic inflammation of patients in chronic hemodialysis (HD) by increasing substitution volumes. To verify this hypothesis, we performed a prospective cross-over study comparing the effect on inflammatory biomarkers of higher convection by MID versus standard convection by post-dilution hemodiafiltration (HDF). Patients under chronic HD were therefore treated by MID and HDF by crossover design. Each treatment period lasted 4 months, with 1 month of wash-out where patients were treated by HD, for a total of 9 months. Primary outcome was the change of serum pre-dialytic C-Reactive Protein (CRP), interleukin 6 (IL-6), IL-1, IL-10, transforming growth factor-β (TGF-β), tumor necrosis factor-α, albumin and pre-albumin. Samples were obtained monthly. Ten HD patients were enrolled (age: 64.9 ± 12.6 years; 70% males; dialytic vintage: 10.6 [2.7–16.2] years). Mean convection volume was 40.1 ± 2.5 L/session in MID and 20.1 ± 2.6 L/session in HDF. A significant reduction of β2-Microglobulin was detected as a result of either treatment. In MID, CRP decreased from 11.3 (3.2–31.0) to 3.1 (1.4–14.4) mg/L (p = 0.007), IL-6 from 12.7 (5.0–29.7) to 8.3 (4.4–14.0) pg/mL (p = 0.003), and TGF-β from 10.6 (7.4–15.6) to 7.4 (5.9–9.3) ng/mL (p = 0.001). A significant reduction of CRP from 8.5 (3.2–31.0) to 4.6 (3.2–31.0) mg/L was also detected in HDF (p = 0.037), whereas no significant reduction of IL-6 (p = 0.147) and TGF-β (p = 0.094) was found. Percentage reduction of IL-6 correlated with mean convective volume in HDF (R = 0.666; p = 0.036) and in MID (R = 0.760; p = 0.020). Therefore, MID and HDF are associated with an attenuation of inflammatory pattern that is correlated with a high convective volume.

Keywords:
Mid-dilution, Hemodiafiltration, Inflammation
1.
Nordio M, Limido A, Maggiore U, et al: Survival in patients treated by long-term dialysis compared with the general population. Am J Kidney Dis 2012; 59: 819–828.
2.
Wang AY, Ninomiya T, Al-Kahwa A, Perkovic V, Gallagher MP, Hawley C, Jardine, MJ: Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis 2014; 63: 968–978.
3.
Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J et al: High-efficiency post-dilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487–97.
4.
Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH et al; CONTRAST investigators: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23: 1087–1096.
5.
Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al; Turkish Online Haemodiafiltration Study: Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28: 192–202.
6.
Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, et al: Mortality risk for patients receiving haemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087–2093.
7.
Peters SA, Bots ML, Canaud B, Davenport A, Grooteman MP, Kircelli F, et al; HDF Pooling Project Investigators: Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant 2016; 31: 978–984.
8.
Kawanishi H: Is there enough evidence to prove that hemodiafiltration is superior? Blood Purif 2018; 46: 3–6.
9.
Ronco C: Hemodiafiltration: technical and clinical issues. Blood Purif 2015; 40(suppl 1): 2–11.
10.
de Roij van Zuijdewijn CL, Nubé MJ, ter Wee PM, Blankestijn PJ, Lévesque R, van den Dorpel MA, Bots ML, Grooteman MP: Treatment time or convection volume in HDF: what drives the reduced mortality risk? Blood Purif 2015; 40: 53–58.
11.
Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al; Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645–654.
12.
Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G,et al; RISCAVID Study Group: Chronic inflammation and mortality in hemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337–2343.
13.
Panichi V, Manca-Rizza G, Paoletti S, Taccola D, Consani C, Filippi C, et al: Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs online haemodiafiltration: a cross-over randomized multicentre trial. Nephrol Dial Transplant 2006; 21: 756–762.
14.
Borrelli S, Minutolo R, De Nicola L, De Simone E, De Simone W, Zito B, et al: Effect of hemodiafiltration with endogenous reinfusion on overt idiopathic chronic inflammation in maintenance hemodialysis patients: a multicenter longitudinal study. Hemodial Int 2014; 18: 758–766.
15.
Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, Glorieux G, et al: Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrol Dial Transplant 2011; 26: 2624–2630.
16.
den Hoedt CH, Bots ML, Grooteman MP, van der Weerd NC, Mazairac AH, Penne EL, et al; CONTRAST Investigators: Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int 2014; 86: 423–432.
17.
Canaud B, Barbieri C, Marcelli D, Bellocchio F, Bowry S, Mari F, et al: Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration. Kidney Int 2015; 88: 1108–1116.
18.
Molina P, Vizcaíno B, Molina MD, Beltrán S, González-Moya M, Mora A, et al: The effect of high-volume online haemodiafiltration on nutritional status and body composition: the ProtEin Stores prEservaTion (PESET) study. Nephrol Dial Transplant 2018; 33: 1223–1235.
19.
Tattersall JE, Ward RA; EUDIAL group: Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant 2013; 28: 542–550.
20.
Marcelli D, Scholz C, Ponce P, Sousa T, Kopperschmidt P, Grassmann A, et al: High-volume post-dilution hemodiafiltration is a feasible option in routine clinical practice. Artif Organs 2014; 39: 142–149.
21.
Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R, Pisoni RL: Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet 2016; 388: 294–306.
22.
Santoro A, Conz PA, De Cristofaro V, Acquistapace I, Gaggi R, Ferramosca E, et al: Mid-dilution: the perfect balance between convection and diffusion. Contrib Nephrol 2005; 149: 107–114.
23.
Krieter DH, Falkenhain S, Chalabi L, et al: Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration. Kidney Int 2005; 67: 349–356.
24.
Krieter DH, Falkenhain S, Chalabi L, Collins G, Lemke HD, Canaud B: Mid-dilution on-line haemodiafiltration in a standard dialyzer configuration. Nephrol Dial Transplant 2005; 20: 155–160.
25.
Santoro A, Ferramosca E, Mancini E, Monari C, Varasani M, Sereni L, et al: Reverse mid-dilution: new way to remove small and middle molecules as well as phosphate with high intrafilter convective clearance. Nephrol Dial Transplant 2007; 22: 2000–2005.
26.
Feliciani A, Riva MA, Zerbi S, Ruggiero P, Plati AR, Cozzi G, et al: New strategies in haemodiafiltration (HDF): prospective comparative analysis between on-line mixed HDF and mid-dilution HDF. Nephrol Dial Transplant 2007; 22: 1672–1679.
27.
Pedrini LA, Feliciani A, Zerbi S, Cozzi G, Ruggiero P: Optimization of mid-dilution haemodiafiltration: technique and performance. Nephrol Dial Transplant 2009; 24: 2816–2824.
28.
Mandolfo S, Borlandelli S, Imbasciati E, Badalamenti S, Graziani G, Sereni L, et al: Pilot study to assess increased dialysis efficiency in patients with limited blood flow rates due to vascular access problems. Hemodial Int 2008; 12: 55–61.
29.
The EBPG Expert Group on Haemodialysis. European Best Practice Guidelines for Haemodialysis: part 1. Nephrol Dial Transplant 2002; 17(suppl 7):S45–S46
30.
Conover WJ: Practical Nstatistics. New York, Wiley, 1971.
31.
Maduell F, Arias M, Vera M, Fontseré N, Blasco M, Barros X, et al: Mid-dilution hemodiafiltration: a comparison with pre- and postdilution modes using the same polyphenylene membrane. Blood Purif 2009; 28: 268–274.
32.
Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, et al; Collaborative Study Group on SMC Membrane. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 2002; 39: 266–273.
33.
Calò LA, Naso A, Carraro G, Wratten ML, Pagnin E, Bertipaglia L, et al: Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 2007; 22: 1413–1419.
34.
Vilar E, Fry AC, Wellsted D, Tattersall JE, Greenwood RN, Farrington K: Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 2009; 4: 1944–1953.
35.
Penne EL, van der Weerd NC, Blankestijn PJ, van den Dorpel MA, Grooteman MP, Nubé MJ, et al: Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol 2010; 5: 80–86.
36.
Panichi V, Scatena A, Rosati A, Giusti R, Ferro G, Malagnino E, et al: High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol Dial Transplant 2015; 30: 682–689.
37.
Mid-HDF Randomized Controlled Study on Outcome (MILESTONE). www.clinicaltrials.gov/ct2/show/NCT01693354.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.